KALA BIO (KALA) Competitors $4.30 -0.15 (-3.37%) Closing price 06/13/2025 03:47 PM EasternExtended Trading$4.23 -0.07 (-1.63%) As of 06/13/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALA vs. SAVA, MGNX, TNYA, HLVX, GNLX, IOBT, TCRX, CHRS, COYA, and PLRXShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Cassava Sciences (SAVA), MacroGenics (MGNX), Tenaya Therapeutics (TNYA), HilleVax (HLVX), Genelux (GNLX), IO Biotech (IOBT), TScan Therapeutics (TCRX), Coherus BioSciences (CHRS), Coya Therapeutics (COYA), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Its Competitors Cassava Sciences MacroGenics Tenaya Therapeutics HilleVax Genelux IO Biotech TScan Therapeutics Coherus BioSciences Coya Therapeutics Pliant Therapeutics Cassava Sciences (NASDAQ:SAVA) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership. Which has preferable earnings & valuation, SAVA or KALA? KALA BIO has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$97.22M-$1.50-1.37KALA BIO$3.89M7.13-$42.20M-$8.24-0.52 Does the media prefer SAVA or KALA? In the previous week, Cassava Sciences and Cassava Sciences both had 1 articles in the media. Cassava Sciences' average media sentiment score of 1.87 equaled KALA BIO'saverage media sentiment score. Company Overall Sentiment Cassava Sciences Very Positive KALA BIO Very Positive Which has more volatility & risk, SAVA or KALA? Cassava Sciences has a beta of -1.99, suggesting that its share price is 299% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.98, suggesting that its share price is 298% less volatile than the S&P 500. Do analysts rate SAVA or KALA? Cassava Sciences currently has a consensus price target of $54.50, suggesting a potential upside of 2,558.54%. KALA BIO has a consensus price target of $13.50, suggesting a potential upside of 213.95%. Given Cassava Sciences' higher probable upside, analysts plainly believe Cassava Sciences is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer SAVA or KALA? KALA BIO received 206 more outperform votes than Cassava Sciences when rated by MarketBeat users. Likewise, 67.11% of users gave KALA BIO an outperform vote while only 64.47% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformCassava SciencesOutperform Votes9864.47% Underperform Votes5435.53% KALA BIOOutperform Votes30467.11% Underperform Votes14932.89% Do insiders and institutionals have more ownership in SAVA or KALA? 38.0% of Cassava Sciences shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 2.4% of Cassava Sciences shares are held by company insiders. Comparatively, 8.3% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is SAVA or KALA more profitable? Cassava Sciences' return on equity of -88.05% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -88.05% -64.98% KALA BIO N/A -448.61%-69.37% SummaryKALA BIO beats Cassava Sciences on 9 of the 14 factors compared between the two stocks. Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.74M$6.88B$5.57B$8.51BDividend YieldN/A2.51%5.27%4.15%P/E Ratio-0.348.5026.7819.65Price / Sales7.13263.11404.49152.18Price / CashN/A65.8538.2534.64Price / Book1.546.526.964.59Net Income-$42.20M$143.48M$3.23B$248.23M7 Day Performance3.86%-0.20%-1.24%-1.07%1 Month Performance31.50%11.63%8.34%3.35%1 Year Performance-27.85%3.21%33.30%13.77% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO3.7513 of 5 stars$4.30-3.4%$13.50+214.0%-28.3%$27.74M$3.89M-0.3430Positive NewsGap DownSAVACassava Sciences4.2698 of 5 stars$2.15-1.8%$54.50+2,434.9%-89.7%$103.86MN/A-1.5630Positive NewsMGNXMacroGenics3.7645 of 5 stars$1.64-7.9%$5.71+248.4%-67.5%$103.47M$152.43M-1.04430Options VolumeGap DownTNYATenaya Therapeutics3.6766 of 5 stars$0.69+8.1%$6.25+811.9%-84.2%$103.10MN/A-0.48110News CoverageGap DownHigh Trading VolumeHLVXHilleVax3.1945 of 5 stars$2.04+2.5%$3.00+47.1%-87.5%$102.29MN/A-0.6620News CoveragePositive NewsGNLXGenelux1.1945 of 5 stars$2.71+5.9%$17.75+555.0%+28.6%$102.26M$8K-2.8510Analyst UpgradeIOBTIO Biotech3.9452 of 5 stars$1.55-3.1%$9.33+502.2%+5.5%$102.12MN/A-1.1330News CoveragePositive NewsAnalyst UpgradeShort Interest ↓TCRXTScan Therapeutics3.7318 of 5 stars$1.77-1.7%$7.80+340.7%-82.8%$101.86M$4.42M-1.67100News CoveragePositive NewsAnalyst DowngradeGap UpCHRSCoherus BioSciences3.9756 of 5 stars$0.85+2.9%$4.68+448.1%-57.2%$99.05M$272.25M-10.68330Positive NewsCOYACoya Therapeutics2.1821 of 5 stars$5.88flat$17.00+189.1%-27.6%$98.34M$3.69M-9.056Gap UpPLRXPliant Therapeutics4.3014 of 5 stars$1.60-1.8%$13.31+732.0%-88.5%$98.22M$1.58M-0.4890Positive NewsAnalyst RevisionGap Down Related Companies and Tools Related Companies Cassava Sciences Competitors MacroGenics Competitors Tenaya Therapeutics Competitors HilleVax Competitors Genelux Competitors IO Biotech Competitors TScan Therapeutics Competitors Coherus BioSciences Competitors Coya Therapeutics Competitors Pliant Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KALA Stock Free KALA Stock Alerts